Status:
COMPLETED
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Lead Sponsor:
Anhui Provincial Hospital
Conditions:
Toxicity, Drug
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Neoadjuvant chemoradiotherapy followed by surgery has been the standard modality for locally advance esophageal carcinoma. According to CROSS study, the pathological complete remission rate achieved b...
Detailed Description
Trial Title Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab for initially inoperable patients with locally advanced esophageal squamous cell carcinoma: A Prospective, One-arm,...
Eligibility Criteria
Inclusion
- 18-75 years old;
- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Esophageal squamous cell carcinoma;
- cT2-4aN0-3M0-1a (AJCC 8th) confirmed by radiological examination;
- Initially inoperable at initial diagnosis confirmed by thoracic surgeons;
- No esophageal hemorrhage and no esophageal fistula at initial diagnosis;
- Treatment naive;
- No contraindications for adjuvant chemoradiotherapy, camrelizumab and nimotuzumab;
- Signature of inform consent.
Exclusion
- younger than 18 years old or older than 75 years old;
- ECOG\>1;
- Esophageal adenocarcinoma, small-cell cancer and other pathological types;
- Presence of esophageal hemorrhage and esophageal fistula at initial diagnosis;
- Previous treatment of chemotherapy, radiotherapy, immune therapy and other treatment;
- Contraindications for chemoradiotherapy, camrelizumab and nimotuzumab;
- No signature of inform consent.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05355168
Start Date
November 1 2021
End Date
March 31 2024
Last Update
December 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provicial Hospital
Hefei, Anhui, China